Lazertinib
Lazcluze · EGFR TKI (3rd-gen)
2024 EGFR TKI; hyponatremia like osimertinib.
Tagrisso · OSI
EGFR TKI · approved 2015 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A third-generation EGFR TKI whose uncommon renal-electrolyte signal is SIADH-type hyponatremia.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Syndrome of inappropriate antidiuretic hormone (SIADH)-type hyponatremia is described at the case level; occasional acute kidney injury and rare proteinuria are reported. True structural kidney injury is not quantified as a discrete endpoint in randomized data, where overall renal adverse events are uncommon. The common osimertinib renal finding is instead a pseudo-decrease in creatinine-based eGFR from inhibited tubular creatinine secretion, quantified for osimertinib specifically by Ilyas et al. (Kidney Med 2026) and, at the cohort level, in the AMBORA real-world analysis: among 238 patients on 38 oral antitumor agents likely to cause pseudo-worsening, mean eGFR fell 6.8 mL/min within 30 days and by >=20 mL/min in 17.2% — a whole-group figure, not an osimertinib-specific rate.Source: Skribek et al., Lung Cancer 2022
Within roughly the first weeks to a few months (around two months in several published cases).
Distilled from: “Reported within roughly the first weeks to a few months of therapy (around two months in several published cases).”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
SIADH reported only at case level; a rare adverse effect PMID 35276629 (opens PubMed in a new tab)
SIADH-mediated hyponatremia described only in case reports PMID 33839042 (opens PubMed in a new tab)
Inhibited tubular creatinine secretion lowers creatinine-based eGFR without a true GFR fall; the AMBORA cohort figure (mean eGFR -6.8 mL/min within 30 days, >=20 mL/min in 17.2%) spans 38 oral antitumor agents, not osimertinib alone PMID 42179809 (opens PubMed in a new tab)
Tap a signature to trace where it strikes the nephron.
SIADH / Hyponatremia strikes: Distal Tubule / Collecting Duct.
SIADH / Hyponatremia
Inappropriate water retention at the collecting duct — high-dose cyclophosphamide.
Third-generation, irreversible EGFR tyrosine kinase inhibitor that covalently binds the C797 residue and is selective for sensitizing EGFR mutations and the T790M resistance mutation while sparing wild-type EGFR. Standard therapy for EGFR-mutant non-small cell lung cancer, including CNS disease.
Class-level context for the major non-renal toxicities of the EGFR TKI class.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Pulmonary
Pneumonitis, ILD, effusions, hypertension
8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dose adjustment is recommended in patients with creatinine clearance (CLcr) 15 - 89 mL/min, as estimated by Cockcroft-Gault. There is no recommended dose of TAGRISSO for patients with end-stage renal disease (CLcr <15 mL/min) [see Clinical Pharmacology (12.3) ].
Kidney rows of the label's dosage tables
From the TAGRISSO label (Sep 2026) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 33,803 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
14,454 of 33,803 reports
Reported with hospitalization
6,560 of 33,803 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2 of the 33,803 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Osimertinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Lazcluze · EGFR TKI (3rd-gen)
2024 EGFR TKI; hyponatremia like osimertinib.
Alkeran · Alkylator
SIADH in high-dose myeloma conditioning; renally cleared.
Temodar · Alkylator
Occasional SIADH; generally renally well tolerated.
Velban · Vinca alkaloid
SIADH and rare Raynaud/vascular events.
Oncovin · Vinca alkaloid
SIADH → hyponatremia.
Navelbine · Vinca alkaloid
SIADH reports.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Osimertinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Osimertinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 25 clinical records among all 34 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.